Vertex Company Overview and Financial Performance

Vertex is a global biotech company that has been a leader in the development of cystic fibrosis treatments for decades. Founded in 1989, Vertex has a long history of innovation and perseverance.

The company's financial performance has been impressive, with a market capitalization of over $50 billion at its peak. This significant valuation is a testament to the company's successful strategy and execution.

Vertex has a strong track record of generating revenue, with a significant portion of it coming from the sales of its cystic fibrosis treatments. In 2020, the company reported $4.8 billion in revenue, a notable increase from the previous year.

The company's financial performance is a result of its focus on research and development, which has led to the approval of several groundbreaking treatments for cystic fibrosis.

Related reading: Broadridge Financial Solutions

Vertex's pricing strategy has been a topic of discussion, particularly in the UK. The company's initial pricing of Orkambi at US$135,000 to US$270,000 per patient per year led to campaigns by parent groups concerned about access to the drug for children and young adults with cystic fibrosis.

In 2019, Vertex was required to destroy 7,880 packs of Orkambi due to expired dates during price negotiations with the NHS. This highlights the challenges of finding a balance between pricing and accessibility.

The company has made efforts to increase access to their cystic fibrosis medications, with agreements in place for countries like the UK, Spain, and Australia. However, the high cost of Trikafta remains a significant barrier to access in many countries.

Vertex's revenue has been steadily increasing, with a projected annual revenue of $11,770 million in 2025. This growth is expected to continue, with estimated revenues of $12,862 million in 2026 and $13,945 million in 2027.

Here is a breakdown of Vertex's projected revenue and earnings per share (EPS) for the next few years:

By 2023, Vertex had reimbursement agreements in 36 countries for their CF medicines, of which 35 are considered high-income countries.

Trikafta has become increasingly available worldwide since its initial approval in 2019. Over 30 countries primarily in high-income nations across North America, Europe, and Oceania reimburse the medication.

About 27% of the estimated CF patients were treated with Trikafta in 2023, with nearly half living in the U.S., 42% in Europe, and 9% in Canada, Israel, Australia, and New Zealand combined.

The high cost of Trikafta presents a significant barrier to access, with patients typically paying a fraction of the cost in countries where it is reimbursed, but the financial burden on healthcare systems remains substantial.

By 2024, Vertex's group of CF medications were "broadly available" in over 60 countries, although access to Cystic Fibrosis medications is still limited in many countries.

Vertex Inc.'s annual revenue was $617.8 million in 2025.

The company's sales per share have been steadily increasing over the years, from $9.83 in 2017 to $37.77 in 2023.

The P/E ratio, which is a measure of how much investors are willing to pay for each dollar of earnings, has varied significantly over the years, ranging from 20.48 in 2018 to 144.10 in 2017.

Here's a breakdown of Vertex Inc.'s P/E ratio over the years:

The equity ratio, which measures the proportion of a company's assets that are financed by shareholders, has been relatively stable, ranging from 57.59% in 2017 to 76.65% in 2022.

Vertex Inc. has not paid a dividend in recent years, with a dividend yield of 0.00% from 2017 to 2023.

Vertex Inc. has a total of 1,755 people employed. This number represents the workforce behind the company's innovative pharmaceuticals and medical research.

The leadership team at Vertex is comprised of experienced professionals who have a strong track record of success. As of the latest information available, the President and Chief Executive Officer of Vertex Inc. is David DeStefano.

Here is a list of some of the key executives at Vertex:

CEO compensation can be a significant topic of discussion, especially when it comes to large companies like Vertex.

In 2015, CEO Jeffrey Leiden's compensation was reported to be around US$48.5 million, a staggering figure that likely raised some eyebrows.

Vertex shareholders took action and opted for a reduction in CEO compensation in 2015 and 2016, resulting in 2016 earnings of US$17.4 million, a significant decrease from the previous year.

Reshma Kewalramani, the current CEO of Vertex, reportedly bought a large portion of the company's stock in August 2025, demonstrating her commitment to the company's success.

Joining a company that truly values its employees can be a game-changer for your career and overall well-being.

Companies like Vertex Pharmaceuticals Inc are great workplaces because they listen to their employees' comments on the Trust Index survey, which helps them understand what makes them tick.

The words used by Vertex employees on the Trust Index survey give insight into what makes a company great.

The management team at Vertex Inc. is a talented group of individuals who work together to drive the company's success. David DeStefano is the President and Chief Executive Officer of Vertex Inc.

Reshma Kewalramani is the current CEO of Vertex, having taken over in a role that also includes being a Director. She has made headlines for her business decisions, including buying a large portion of the company's stock in August 2025.

The company's board of directors is made up of experienced professionals, including Independent Directors such as Alan M. Garber, Diana L. McKenzie, and Lloyd A. Carney. These individuals provide guidance and oversight to the management team.

Here is a list of some of the key members of the management team at Vertex Inc.:

The company has a total of 1,755 people employed at Vertex Inc.

Vertex's financial performance has been impressive, with an annual revenue of $617.8 million in 2025.

The company's revenue is expected to continue growing, with estimates suggesting $11,770 million in 2025, $12,862 million in 2026, $13,945 million in 2027, and $15,247 million in 2028.

Vertex's net profit has also been increasing, reaching $4,855 million in 2025, $5,359 million in 2026, $5,957 million in 2027, and $6,720 million in 2028.

Here's a breakdown of Vertex's key financial metrics:

The annual revenue of Vertex Inc. was $617.8 million in 2025.

In 2026, Vertex Inc. is estimated to have a revenue of $12,862 million, according to the average estimate of 12 analysts.

This represents a significant increase from the previous year's revenue of $11,770 million.

Here's a breakdown of the estimated revenue for the next few years:

These estimates are based on the average of multiple analysts, providing a reliable forecast of the company's revenue growth.

The SIC code for Vertex Inc. is 737, 73.

You can look up the SIC code for any company to get an idea of its industry classification.

The initial pricing of Orkambi in the UK was a staggering US$135,000 to US$270,000 per patient per year.

This led to campaigns by parent groups concerned about limited access to the drug for children and young adults with cystic fibrosis.

Vertex was legally required to destroy 7,880 packs of Orkambi that reached their expiry dates during price negotiations with the NHS in March 2019.

The high prices of Orkambi and other Vertex cystic fibrosis medications led to allegations of unfair pricing by the UK's National Health Service.

In October 2023, NICE declined to recommend Vertex's cystic fibrosis drugs Kaftrio, Symkevi, and Orkambi for use in CF patients, citing their high costs as beyond the acceptable range for NHS resources.

Vertex's shareholders include institutional investors such as The Vanguard Group, Inc. and BlackRock, Inc.

Vertex's largest shareholders are the company's founders, including Joshua S. Boger and Robert E. Hogan.

These insiders have significant control over the company's direction and decision-making processes.

Insider Activity is a crucial aspect of a company's financial health, and it's essential to understand what's going on behind the scenes. Insider activity refers to the buying and selling of company shares by individuals with access to non-public information, such as executives, directors, and large shareholders.

According to the Vertex Pharmaceuticals Insider Activity, several executives and directors have been actively buying and selling company shares over the past few months. For instance, Bhatia Sangeeta N. bought 1,292 shares on August 7, 2024, at a price of $152.74.

The frequency and volume of insider trades can provide valuable insights into a company's prospects. In the case of Vertex Pharmaceuticals, several insiders have been selling shares, including ALTSHULER DAVID, who sold 15,000 shares on November 14, 2024, at a price of $478.56.

Here's a breakdown of some notable insider trades:

Insider trading can be a double-edged sword, as it can indicate both confidence in a company's future prospects and a desire to cash out before the company's stock price drops. It's essential to keep an eye on insider activity and consider it when making investment decisions.

As we dive into shareholder and insider activity, let's start with the basics. The largest shareholder of Vertex Pharmaceuticals is actually freefloat, holding a whopping 99.75% of the company.

This is a significant difference from traditional ownership structures, where a single entity or individual might hold a majority stake. In Vertex's case, the freefloat is a collection of smaller investors who own a tiny fraction of the company.

The next largest shareholder is Capital Research & Management Co., which holds a significant 20.47% of the company through its World Investors and Global Investors entities.

Here's a breakdown of the top shareholders in Vertex Pharmaceuticals:

The Vanguard Group, Inc. is another significant player, holding 8.65% of the company through its main entity and a subsidiary.

Vertex Pharmaceuticals has a rich history of milestones and events that have shaped the company into what it is today. Vertex's Annual General Meeting in 2024 had a notable Actual EPS of 13.890 USD.

The company has a consistent track record of releasing earnings reports, with the Q4 2023 Earnings Release being one of the most recent, reporting an Actual EPS of 3.710 USD. Vertex's Q3 2023 Earnings Release also had a notable Actual EPS of 3.970 USD.

Here's a brief overview of some of the key events in Vertex's recent history:

Genetic therapies have made significant progress in recent years, and Vertex is at the forefront of this innovation. In 2015, Vertex entered into a research collaboration with CRISPR Therapeutics to develop gene-editing therapies for genetic diseases.

One notable example of this collaboration is CTX001, which received Orphan Drug Designation from the U.S. Food and Drug Administration in May 2020 for transfusion-dependent beta thalassemia.

Vertex has also collaborated with Moderna to develop new mRNA-based therapeutics to treat cystic fibrosis (CF), with a deal worth $40 million upfront and up to $275 million in milestone payments.

This collaboration with Moderna is part of a larger effort by Vertex to develop gene therapies for various diseases, including sickle cell disease, beta thalassemia, and cystic fibrosis.

In 2019, Vertex established a research collaboration with Arbor Biotechnologies to discover novel proteins to advance the development of new gene-editing therapies for cystic fibrosis and four other diseases. The deal is worth up to $1.2 billion in milestones, along with undisclosed up-front payments.

Vertex's product pipeline includes drug regimens targeting specialty diseases like sickle cell disease, beta thalassemia, Duchenne muscular dystrophy, alpha-1 antitrypsin deficiency, pain, and APOL1-mediated kidney diseases.

Here are some of the diseases that Vertex is working to develop gene therapies for:

The Vertex Pharmaceuticals company has a long history of significant events that have shaped its growth and performance. Their Annual General Meetings have seen a steady increase in earnings per share (EPS) over the years.

The first notable event was the Annual General Meeting on May 15, 2024, where the EPS was $13.890 USD. This was a significant milestone for the company.

The company's Earnings Reports have also provided valuable insights into its financial performance. The Q4 2023 Earnings Release, for example, reported an EPS of $3.710 USD on February 5, 2024.

Here's a summary of the company's recent Earnings Reports:

These reports demonstrate the company's steady growth and financial performance over the years.

Vertex is based in King of Prussia, Pennsylvania.